Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke
Group Managing Director, Kate Quirke
Source: Alcidion Group
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Alcidion Group (ALC) expands the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD)
  • The contract extension will generate around an additional $1.8 million in revenue over the next three years
  • Last year, the parties signed a 12 month contract with Sydney LHD to manage the care of COVID-19 patients in home isolation
  • Alongside this contract, Alcidion and Sydney LHD will work together to deploy the patient app, Miya Care
  • Alcidion is up 4.29 per cent and is trading at 36.5 cents per share at 1:45 pm AEDT

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).

The contract extension will generate an additional estimated $1.8 million in revenue over the next three years.

Last year, the parties signed a 12 month contract with Sydney LHD for Miya. The agreement was established to manage the care of COVID-19 patients in home isolation.

Miya provides RPA Virtual Hospital (rpavirtual) clinicians with a clinical monitoring dashboard that consolidates information to support remote patient care. The technology aims to reduce required hospitalisations, support an increase in the numbers of patients who can be treated and improve recovery outcomes.

Alongside this contract, Alcidion and Sydney LHD will work together to deploy the patient app, Miya Care.

Speaking on this announcement is Managing Director Kate Quirke.

“We are very excited to build on our initial implementation of Miya Precision with Sydney Local Health District through this project that highlights the flexibility and scalability of our platform as a key enabler of new and innovative models of care,” Ms Quirke said.

“We believe Alcidion can play a meaningful role in the development of virtual care across the hospital system in Australia and this partnership with Sydney Local Health District provides a strong validation of that.”

Alcidion was up 4.29 per cent, trading at 36.5 cents per share at 1:45 pm AEDT.

ALC by the numbers
More From The Market Online
The Market Online Video

Listen: From the Wire – Paradigm Biopharma CEO and Founder Paul Rennie

From The Wire: Senior markets reporter Jonathon Davidson sat down with Paradigm Biopharmaceuticals chief executive officer…
Lung imaging concept

Biotech lung imaging darling 4DX Medical back at $2.20/sh on Miami U contract

4DX Medical has seen its price jump back to $2.20/sh, as its next-gen lung imaging scan…
Chuffed bloke

Race Oncology’s placement-at-a-premium rewarded as shares jump +8%

Race Oncology has completed its recent A$3.2M placement – something that shareholders on the HotCopper forums…

Effective as an IV drug, a gel, and now an inhaler – Recce’s R327 can’t stop winning

Recce flagship antibacertial and anti-infective drug R327 has in a model that shows the drug could…